MA52707A - Formulations de dantrolène et leurs procédés d'utilisation - Google Patents
Formulations de dantrolène et leurs procédés d'utilisationInfo
- Publication number
- MA52707A MA52707A MA052707A MA52707A MA52707A MA 52707 A MA52707 A MA 52707A MA 052707 A MA052707 A MA 052707A MA 52707 A MA52707 A MA 52707A MA 52707 A MA52707 A MA 52707A
- Authority
- MA
- Morocco
- Prior art keywords
- processes
- dantrolene formulations
- dantrolene
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862674394P | 2018-05-21 | 2018-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52707A true MA52707A (fr) | 2021-03-31 |
Family
ID=66821419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052707A MA52707A (fr) | 2018-05-21 | 2019-05-21 | Formulations de dantrolène et leurs procédés d'utilisation |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210236467A1 (https=) |
| EP (1) | EP3796889A1 (https=) |
| JP (2) | JP7762489B2 (https=) |
| KR (1) | KR20210011961A (https=) |
| CN (1) | CN112135605A (https=) |
| AU (1) | AU2019272577B2 (https=) |
| BR (1) | BR112020023012A2 (https=) |
| CA (1) | CA3101093A1 (https=) |
| IL (1) | IL278575B1 (https=) |
| MA (1) | MA52707A (https=) |
| MX (2) | MX2020012464A (https=) |
| SG (1) | SG11202011121UA (https=) |
| UA (1) | UA127661C2 (https=) |
| WO (1) | WO2019226621A1 (https=) |
| ZA (1) | ZA202006986B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419795A (zh) * | 2020-05-09 | 2020-07-17 | 上药东英（江苏）药业有限公司 | 一种注射用丹曲林钠混悬剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1361092A (en) | 1992-03-10 | 1993-10-05 | Kyukyu Pharmaceutical Co., Ltd. | Pharmaceutical preparation for percutaneous administration |
| JPH06263636A (ja) * | 1993-03-12 | 1994-09-20 | Kiyoshi Kataoka | 脳または高次神経疾患治療剤 |
| US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| EP1603513B1 (en) * | 2003-03-04 | 2020-12-30 | Lyotropic Therapeutics, Inc. | Dantrolene compositions |
| WO2010126818A1 (en) * | 2009-04-27 | 2010-11-04 | Usworldmeds Llc | Intranasal delivery system for dantrolene |
| WO2019175761A1 (en) * | 2018-03-12 | 2019-09-19 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use dantrolene compositions |
-
2019
- 2019-05-21 AU AU2019272577A patent/AU2019272577B2/en active Active
- 2019-05-21 MX MX2020012464A patent/MX2020012464A/es unknown
- 2019-05-21 BR BR112020023012-0A patent/BR112020023012A2/pt unknown
- 2019-05-21 SG SG11202011121UA patent/SG11202011121UA/en unknown
- 2019-05-21 KR KR1020207036289A patent/KR20210011961A/ko not_active Ceased
- 2019-05-21 EP EP19729994.4A patent/EP3796889A1/en active Pending
- 2019-05-21 JP JP2020564888A patent/JP7762489B2/ja active Active
- 2019-05-21 CN CN201980033640.3A patent/CN112135605A/zh active Pending
- 2019-05-21 US US17/052,572 patent/US20210236467A1/en not_active Abandoned
- 2019-05-21 MA MA052707A patent/MA52707A/fr unknown
- 2019-05-21 UA UAA202008098A patent/UA127661C2/uk unknown
- 2019-05-21 CA CA3101093A patent/CA3101093A1/en active Pending
- 2019-05-21 WO PCT/US2019/033260 patent/WO2019226621A1/en not_active Ceased
-
2020
- 2020-11-09 IL IL278575A patent/IL278575B1/en unknown
- 2020-11-10 ZA ZA2020/06986A patent/ZA202006986B/en unknown
- 2020-11-19 MX MX2025002392A patent/MX2025002392A/es unknown
-
2023
- 2023-11-10 JP JP2023191895A patent/JP2024023270A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019272577B2 (en) | 2024-08-08 |
| JP2021524855A (ja) | 2021-09-16 |
| CN112135605A (zh) | 2020-12-25 |
| ZA202006986B (en) | 2024-04-24 |
| MX2025002392A (es) | 2025-04-02 |
| IL278575A (https=) | 2021-01-31 |
| IL278575B1 (en) | 2026-03-01 |
| UA127661C2 (uk) | 2023-11-22 |
| JP2024023270A (ja) | 2024-02-21 |
| CA3101093A1 (en) | 2019-11-28 |
| SG11202011121UA (en) | 2020-12-30 |
| AU2019272577A1 (en) | 2020-11-26 |
| BR112020023012A2 (pt) | 2021-02-02 |
| KR20210011961A (ko) | 2021-02-02 |
| JP7762489B2 (ja) | 2025-10-30 |
| MX2020012464A (es) | 2021-02-09 |
| EP3796889A1 (en) | 2021-03-31 |
| WO2019226621A1 (en) | 2019-11-28 |
| US20210236467A1 (en) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
| EP3678681A4 (en) | INTERLEUKIN-18 VARIANTS AND METHODS OF USE | |
| MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA47691A (fr) | Anticorps anti-cd33 et leurs procédés d'utilisation | |
| EP3790596A4 (en) | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE | |
| EP3775203A4 (en) | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | |
| MA50077A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| EP3684821A4 (en) | ANTI-HLA-A2 ANTIBODIES AND METHOD OF USING THEREOF | |
| MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52203A (fr) | Récepteurs chimères pour dll3 et leurs procédés d'utilisation | |
| EP3645741A4 (en) | ANTI-4-1BB ANTIBODIES AND METHOD OF MANUFACTURING AND USING | |
| MA52963A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
| MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
| EP3386536A4 (en) | COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF | |
| MA50912A (fr) | Inhibiteurs d'acss2 et leurs procédés d'utilisation | |
| MA54148A (fr) | Mélanges et compositions comprenant de la 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one et leurs procédés d'utilisation | |
| MA52416A (fr) | Anticorps b7-h4 et leurs procédés d'utilisation | |
| EP3846808A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
| MA50516A (fr) | Anticorps anti-apoc3 et leurs procédés d'utilisation |